Long-term follow-up of the AML97 study for patients aged 60 years and above with acute myeloid leukaemia: a study of the East German Haematology and Oncology Study Group (OSHO)

Journal of Cancer Research and Clinical Oncology

Volumn 142, Issue 1, 2016, Pages 305-315

  Kahl, C ^a,b   Krahl, R ^c   Becker, C ^c   Al Ali, H K ^c   Sayer, H G ^d,e   Schulze, A ^d   Herold, M ^d   Hanel M ^f   Scholl, S ^e   Hochhaus, A ^e   Uharek, L ^g   Maschmeyer, G ^h   Haehling, D ⁱ   Junghanss C ^b   Peter, N ^j   Kampfe D ^k   Kettner, E ^a   Heinicke, T ^l   Fischer, T ^l   Kreibich, U ^m   Wolf, H H ⁿ   Niederwieser, D ^c   more..

^a Klinikum Magdeburg gGmbH   (Germany)

^b UNIVERSITY OF ROSTOCK   (Germany)

^c UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^d HELIOS KLINIKUM ERFURT   (Germany)

^e JENA UNIVERSITY HOSPITAL   (Germany)

^f KLINIKUM CHEMNITZ   (Germany)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h Ernst von Bergmann Clinic   (Germany)

ⁱ Klinikum Schwerin   (Germany)

^j Klinikum Cottbus   (Germany)

^k Praxis für Hämatologie und Onkologie   (Germany)

^l OTTO VON GUERICKE UNIVERSITY   (Germany)

^m Heinrich Braun Hospital   (Germany)

ⁿ MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

more..

Author keywords

AML; Elderly; Long term follow up; Therapy

Indexed keywords

AMSACRINE; ANTHRACYCLINE; CYTARABINE; ETOPOSIDE; IDARUBICIN; MITOXANTRONE; PREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TIOGUANINE; ANTINEOPLASTIC AGENT;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RESEARCH; CLINICAL PROTOCOL; COMORBIDITY; CYTOGENETICS; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HUMAN; INFECTIOUS COMPLICATION; KARYOTYPE; LEUKEMIA REMISSION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDIAN SURVIVAL TIME; MIDDLE AGED; MOLECULAR THERAPY; MYCOSIS; NEUTROPENIA; NONMYELOABLATIVE CONDITIONING; PNEUMONIA; PRIORITY JOURNAL; PYREXIA IDIOPATHICA; REMISSION; RISK ASSESSMENT; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; VERY ELDERLY; CANCER STAGING; GERMANY; LEUKEMIA, MYELOID, ACUTE; MORTALITY; MULTIMODALITY CANCER THERAPY; PALLIATIVE THERAPY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TIME FACTOR;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; GERMANY; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NEOPLASM STAGING; PALLIATIVE CARE; PROGNOSIS; REMISSION INDUCTION; SURVIVAL RATE; TIME FACTORS;

EID: 84953637893     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-015-2045-8     Document Type: Article

References (39)

1. Al-Ali HK, Jaekel N, Junghanss C, Maschmeyer G, Krahl R, Cross M, Hoppe G, Niederwieser D (2012) Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study. Leuk Lymphoma 53:110–117
2. Al-Ali HK, Jaekel N, Niederwieser D (2014) The role of hypomethylating agents in the treatment of elderly patients with AML. J Geriatr Oncol 5:89–105
3. Bloomfield CD, Lawrence D, Byrd JC, Carroll A, Pettenati MJ, Tantravahi R, Patil SR, Davey FR, Berg DT, Schiffer CA et al (1998) Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 58:4173–4179
4. Buchner T, Hiddemann W, Wormann B, Loffler H, Gassmann W, Haferlach T, Fonatsch C, Haase D, Schoch C, Hossfeld D et al (1999) Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood 93:4116–4124
5. Buchner T, Hiddemann W, Schoch C, Haferlach T, Sauerland MC, Heinecke A (2001) Acute myeloid leukaemia (AML): treatment of the older patient. Best Pract Res Clin Haematol 14:139–151
6. Buchner T, Hiddemann W, Berdel W, Wormann B, Schoch C, Loffler H, Haferlach T, Schumacher A, Staib P, Balleisen L et al (2002) Acute myeloid leukemia: treatment over 60. Rev Clin Exp Hematol 6:46–59
7. Buchner T, Berdel WE, Schoch C, Haferlach T, Serve HL, Kienast J, Schnittger S, Kern W, Tchinda J, Reichle A et al (2006) Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. J Clin Oncol 24:2480–2489
8. Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, Pettenati MJ, Patil SR, Rao KW, Watson MS et al (2002) Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 100:4325–4336
9. Catovsky D, Matutes E (1992) The classification of acute leukaemia. Leukemia 6(Suppl 2):1–6
10. Catovsky D, Matutes E, Buccheri V, Shetty V, Hanslip J, Yoshida N, Morilla R (1991) A classification of acute leukaemia for the 1990s. Ann Hematol 62:16–21
11. Champlin R (2013) Reduced intensity allogeneic hematopoietic transplantation is an established standard of care for treatment of older patients with acute myeloid leukemia. Best Pract Res Clin Haematol 26:297–300
12. Cheson BD, Cassileth PA, Head DR, Schiffer CA, Bennett JM, Bloomfield CD, Brunning R, Gale RP, Grever MR, Keating MJ et al (1990) Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 8:813–819
13. Feinstein LC, Sandmaier BM, Hegenbart U, McSweeney PA, Maloney DG, Gooley TA, Maris MB, Chauncey TR, Bruno B, Appelbaum FR et al (2003) Non-myeloablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission. Br J Haematol 120:281–288
14. Goldstone AH, Burnett AK, Wheatley K, Smith AG, Hutchinson RM, Clark RE (2001) Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood 98:1302–1311
15. Green S, Weiss GR (1992) Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 10:239–253
16. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A et al (1998) The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children’s Leukaemia Working Parties. Blood 92:2322–2333
17. Gyurkocza B, Storb R, Storer BE, Chauncey TR, Lange T, Shizuru JA, Langston AA, Pulsipher MA, Bredeson CN, Maziarz RT et al (2010) Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. J Clin Oncol 28:2859–2867
18. Hiddemann W, Schleyer E, Unterhalt M, Zuhlsdorf M, Rolf C, Reuter C, Kewer U, Uhrmeister C, Wormann B, Buchner T (1992) Differences in the intracellular pharmacokinetics of cytosine arabinoside (AraC) between circulating leukemic blasts and normal mononuclear blood cells. Leukemia 6:1273–1280
19. Jaffe ES (2001) Pathology and genetics of tumors of haematopoietic and lymphoid tissues. In: Jaffe ES, Harris NL, Stein JE, Variakojis D (eds) World Health Organization classification of tumors. IARC Press, Lyon
20. Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, Lindsley RC, Mermel CH, Burtt N, Chavez A et al (2014) Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 371:2488–2498
21. Kahl C, Storer B, Mielcarek M, Maris M, Sandmaier BM, Maloney D, Chauncey T, Niederwieser D, McSweeney P, Bruno B et al (2005) Relapse risk after nonmyeloablative hematopoietic cell transplantation for malignant diseases. Blood 110(7):2744–2748
22. Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, Gau JP, Chou WC, Buckstein R, Cermak J et al (2012) Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 30:2670–2677
23. Karnofsky D, Burchenal J (1949) The Clinical Evaluation of Chemotherapeutic Agents in Cancer. In: MacLeod C (ed) Evaluation of Chemotherapeutic Agents. Columbia University Press, New York
24. Kern W, Aul C, Maschmeyer G, Schonrock-Nabulsi R, Ludwig WD, Bartholomaus A, Bettelheim P, Wormann B, Buchner T, Hiddemann W (1998) Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison. Leukemia 12:1049–1055
25. Kern W, Schoch C, Haferlach T, Braess J, Unterhalt M, Wormann B, Buchner T, Hiddemann W (2000) Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: relevance of cytogenetic abnormalities. Leukemia 14:226–231
26. Lopez A, de la Rubia J, Martin G, Martinez J, Cervera J, Jarque I, Sempere A, Plume G, Saavedra S, Regadera A et al (2001) Recent improvements in outcome for elderly patients with de novo acute myeloblastic leukemia. Leuk Res 25:685–692
27. Mantovani L, Hasenclever D, Krahl R, Ponisch W, Herold M, Pasold R, Fiedler F, Dolken G, Kampfe D, Schmoll HJ et al (2002) Intermediate-dose cytarabine treatment delivered at moderate infusion rates for de novo acute myeloid leukemia-results of a phase I-II study. Leuk Lymphoma 43:265–274
28. Mengis C, Aebi S, Tobler A, Dahler W, Fey MF (2003) Assessment of differences in patient populations selected for excluded from participation in clinical phase III acute myelogenous leukemia trials. J Clin Oncol 21:3933–3939
29. Mitelman F (1995) An international system for human cytogenetic nomenclature. Karger, Basel
30. Nelson RP Jr, Yu M, Schwartz JE, Robertson MJ, Hromas R, Fausel CA, Vance GH, Dlouhy SR, Baute JA, Cox EA et al (2010) Long-term disease-free survival after nonmyeloablative cyclophosphamide/fludarabine conditioning and related/unrelated allotransplantation for acute myeloid leukemia/myelodysplasia. Bone Marrow Transplant 45:1300–1308
31. Othus M, Kantarjian H, Petersdorf S, Ravandi F, Godwin J, Cortes J, Pierce S, Erba H, Faderl S, Appelbaum FR et al (2014) Declining rates of treatment-related mortality in patients with newly diagnosed AML given ‘intense’ induction regimens: a report from SWOG and MD Anderson. Leukemia 28:289–292
32. Pleyer L, Stauder R, Burgstaller S, Schreder M, Tinchon C, Pfeilstocker M, Steinkirchner S, Melchardt T, Mitrovic M, Girschikofsky M et al (2013) Azacitidine in patients with WHO-defined AML—results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group. J Hematol Oncol 6:32
33. Plunkett W, Liliemark JO, Estey E, Keating MJ (1987a) Saturation of ara-CTP accumulation during high-dose ara-C therapy: pharmacologic rationale for intermediate-dose ara-C. Semin Oncol 14:159–166
34. Plunkett W, Nowak B, Keating MJ (1987b) Effect of amsacrine on ara-CTP cellular pharmacology in human leukemia cells during high-dose cytarabine therapy. Cancer Treat Rep 71:479–483
35. Schaich M, Illmer T, Aulitzky W, Bodenstein H, Clemens M, Neubauer A, Repp R, Schakel U, Soucek S, Wandt H et al (2002) Intensified double induction therapy with high dose mitoxantrone, etoposide, m-amsacrine and high dose ara-C for elderly acute myeloid leukemia patients aged 61-65 years. Haematologica 87:808–815
36. Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman P, Lee EJ, Moore JO, Powell BL, Schiffer CA (1995) Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N Engl J Med 332:1671–1677
37. Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman PP, Lee EJ, Moore JO, Powell BL, Baer MR et al (2001) Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood 98:548–553
38. Thepot S, Itzykson R, Seegers V, Recher C, Raffoux E, Quesnel B, Delaunay J, Cluzeau T, Marfaing KA, Koka A, Stamatoullas A et al (2014) Azacitidine in untreated acute myeloid leukemia: a report on 149 patients. Am J Hematol 89(4):410–416
39. Wang ES (2014) Treating acute myeloid leukemia in older adults. Hematol Am Soc Hematol Educ Program 2014:14–20